Interaction Checker

Interações de Riluzol

Riluzol (Rilutek, Tiglutik, Exservan) tem 36 interações documentadas nas bulas da FDA e nas fichas informativas que indexamos (graves: 0; moderadas: 33; leves: 3; casos em que uma bula relata não haver interação significativa: 0). Cada item abaixo cita a frase em que se baseia. Esta página de medicamento é um ponto de partida, não um veredito para a sua situação.

Interações segundo a bula

Interações moderadas (33)

  • Canabidiol (medicamento de prescrição)anticonvulsivanteModerada

    Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (bula de Riluzol, Interações medicamentosas)

  • CarbamazepinaanticonvulsivanteModerada

    Strong to moderate CYP1A2 inducers: Co-administration may result in decreased efficacy ( 7.2 ) (bula de Riluzol, Interações medicamentosas)

  • Cimetidinabloqueador H2Moderada

    Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (bula de Riluzol, Interações medicamentosas)

  • CiprofloxacinofluoroquinolonaModerada

    Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (bula de Riluzol, Interações medicamentosas)

  • Deferasiroxsuplemento de ferroModerada

    Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (bula de Riluzol, Interações medicamentosas)

  • Desogestrel + etinilestradiolanticoncepcional oralModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (bula de Riluzol, Interações medicamentosas)

  • Diacetato de etinodiol + etinilestradiolanticoncepcional oralModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (bula de Riluzol, Interações medicamentosas)

  • Drospirenona + etinilestradiolanticoncepcional oralModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (bula de Riluzol, Interações medicamentosas)

  • EstradiolestrogênioModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (bula de Riluzol, Interações medicamentosas)

  • Estradiol + dienogesteanticoncepcional oralModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (bula de Riluzol, Interações medicamentosas)

  • Estradiol + noretisteronaestrogênioModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (bula de Riluzol, Interações medicamentosas)

  • Estrogênios conjugadosestrogênioModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (bula de Riluzol, Interações medicamentosas)

  • Estrogênios conjugados + bazedoxifenoestrogênioModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (bula de Riluzol, Interações medicamentosas)

  • Estrogênios esterificados + metiltestosteronaestrogênioModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (bula de Riluzol, Interações medicamentosas)

  • Etonogestrel + etinilestradiolestrogênioModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (bula de Riluzol, Interações medicamentosas)

  • FluvoxaminaISRSModerada

    Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (bula de Riluzol, Interações medicamentosas)

  • FulvestrantoestrogênioModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (bula de Riluzol, Interações medicamentosas)

  • LevonorgestrelprogestinaModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (bula de Riluzol, Interações medicamentosas)

  • Levonorgestrel + etinilestradiolanticoncepcional oralModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (bula de Riluzol, Interações medicamentosas)

  • Lopinavir + ritonavirantirretroviralModerada

    Strong to moderate CYP1A2 inducers: Co-administration may result in decreased efficacy ( 7.2 ) (bula de Riluzol, Interações medicamentosas)

  • MedroxiprogesteronaprogestinaModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (bula de Riluzol, Interações medicamentosas)

  • MegestrolprogestinaModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (bula de Riluzol, Interações medicamentosas)

  • MexiletinaantiarrítmicoModerada

    Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (bula de Riluzol, Interações medicamentosas)

  • Mifepristonainibidor da CYP3A4Moderada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (bula de Riluzol, Interações medicamentosas)

  • Norelgestromina + etinilestradiolestrogênioModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (bula de Riluzol, Interações medicamentosas)

  • NoretisteronaprogestinaModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (bula de Riluzol, Interações medicamentosas)

  • Noretisterona + etinilestradiolanticoncepcional oralModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (bula de Riluzol, Interações medicamentosas)

  • Norgestimato + etinilestradiolanticoncepcional oralModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (bula de Riluzol, Interações medicamentosas)

  • Norgestrel + etinilestradiolanticoncepcional oralModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (bula de Riluzol, Interações medicamentosas)

  • ProgesteronaprogestinaModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (bula de Riluzol, Interações medicamentosas)

  • RitonavirantirretroviralModerada

    Strong to moderate CYP1A2 inducers: Co-administration may result in decreased efficacy ( 7.2 ) (bula de Riluzol, Interações medicamentosas)

  • Viloxazinainibidor da recaptação de noradrenalinaModerada

    Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (bula de Riluzol, Interações medicamentosas)

  • Zileutonainibidor da CYP1A2Moderada

    Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (bula de Riluzol, Interações medicamentosas)

Menções leves (3)

  • Alopurinolinibidor da xantina oxidaseLeve

    Hepatotoxic Drugs Clinical trials in ALS patients excluded patients on concomitant medications which were potentially hepatotoxic (e.g., allopurinol, methyldopa, sulfasalazine). (bula de Riluzol, Interações medicamentosas)

  • Metildopaanti-hipertensivoLeve

    Hepatotoxic Drugs Clinical trials in ALS patients excluded patients on concomitant medications which were potentially hepatotoxic (e.g., allopurinol, methyldopa, sulfasalazine). (bula de Riluzol, Interações medicamentosas)

  • SulfassalazinasulfonamidaLeve

    Hepatotoxic Drugs Clinical trials in ALS patients excluded patients on concomitant medications which were potentially hepatotoxic (e.g., allopurinol, methyldopa, sulfasalazine). (bula de Riluzol, Interações medicamentosas)

Verifique Riluzol com tudo o que você toma. Adicione sua lista completa; todos os pares são verificados de uma vez.

Abrir no verificador

Não é aconselhamento médico. A gravidade reflete a redação da bula, não as suas circunstâncias. Um alerta “grave” pode ser rotina sob supervisão, e um “leve” pode ser importante em doses altas. Pergunte a um farmacêutico.